Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 in locally advanced or metastatic bladder cancer
NCT05248789Phase 2Terminated
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OH2 in bladder cancer, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd. Primary endpoint: Objective Response Rate at 2 years. Started May 2022; status: terminated.
02
Drugs
OH2
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05248789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248789.